Tideglusib (NP-12 NP031112) is a potent selective and irreversible small molecule non-ATP-competitive GSK3 inhibitor that has been investigated as a potential treatment for Alzheimer’s disease and paralysis supranuclear palsy in Phase IIa and IIb clinical trials.
This page contains content from the copyrighted Wikipedia article "Tideglusib"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
